Salt Lake City, UT – March 10, 2008 –Researchers in Canada recently published a study validating the scientific principles behind Anecare’s ANEclear anesthetic recovery device.

The study shows that a patient’s recovery from sevoflurane anesthesia is greatly accelerated by sustaining or slightly increasing a patient’s carbon dioxide level while hyperventilating the patient during emergence.

Patients who emerged from anesthesia using this practice were ready for discharge from the Post Anesthesia Care Unit (PACU) 35% sooner than patients who did not experience hyperventilation and higher CO2 levels at emergence. 

“We know that increased CO2 during emergence increases cerebral blood flow and spontaneous respiration to actively and rapidly clear inhaled anesthetics.  This particular study reinforces Anecare’s premise of the ideal emergence profile,” said Michael Slatter, CEO of Anecare.  “The result is a patient who is more alert at emergence, and one who is ready for discharge from the PACU 35% sooner.”

The ANEclear anesthetic recovery device was designed to allow physicians to hyperventilate a patient at emergence while maintaining or slightly elevating CO2 levels.  This emergence profile, when combined with the ANEclear’s anesthetic absorber, results in active removal of the inhaled anesthetic from a patient and improves their safety and recovery in both the Operating Room and the PACU.

“This has been a difficult outcome to achieve in the past because when a physician hyperventilates a patient to speed the removal of anesthetic from a patient’s lungs, the patient’s CO2 level drops,” said Dr. Dwayne Westenskow, Senior Technical Director at Anecare.  “If the CO2 level drops, so does cerebral blood flow which slows removal of the anesthetic from the brain.  You have to clear the anesthetic from the brain and the lungs if you want a rapid recovery from anesthesia, and the ANEclear allows for both.”

The Canadian researchers also found that time to extubation was decreased by roughly 50%, and recovery time in the operating room was reduced from 15 minutes to 7.6 minutes.

“It is true that patients experience a faster recovery from inhaled anesthesia,” said Slatter, “and hospitals and clinics are able to improve their efficiency and patient throughput when they use the ANEclear, but as clinicians and patients tell us, the overriding outcome is that patients just do better.”

The study “Isocapnic Hyperpnoea and Recovery Time after Anesthesia with Sevoflurane” was conducted by physicians and researchers in Toronto, Canada and was published in Anesthesia & Analgesia, Vol. 106, No. 2 in February, 2008.

About Anecare, Inc.
Anecare is an emerging, US-based global company created to commercialize innovative products from a team of world-renowned researchers who have made improving the quality of anesthesia care their life’s work. Collectively, this team holds more than 60 U.S. patents in anesthesia and respiratory care. Over nearly 25 years, these patents have resulted in a myriad of successful products sold by well known multinational anesthesia and respiratory companies. In late 2004, this team founded Anecare to commercialize their latest innovations. Along with this founding group, Anecare has hired other key individuals, each with unique talents and more than 20-years of individual experience in manufacturing, marketing, and selling medical devices.

# # #

For more information, contact Ryan Brooks at Anecare at 801-977-8877.


Learn More
ANECARE, LLC. 3333 W. PARKWAY BLVD., SALT LAKE CITY, UT 84119    PH. 801.977.8877  FAX 801.977.0363    COPYRIGHT 2011 - 2012, ANECARE LLC, ALL RIGHTS RESERVED